Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Article Date
May 20, 2024
This article is featured on another website.
Go to article
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.